US 12,350,366 B2
Aqueous ophthalmic solutions of phentolamine and medical uses thereof
Alan Meyer, North Riverside, IL (US)
Assigned to Opus Genetics, Inc., Farmington Hills, MI (US)
Filed by Opus Genetics, Inc., Farmington Hills, MI (US)
Filed on Dec. 13, 2023, as Appl. No. 18/538,502.
Application 18/538,502 is a continuation of application No. 17/401,604, filed on Aug. 13, 2021, granted, now 11,844,858, issued on Dec. 19, 2023.
Application 17/401,604 is a continuation of application No. 16/398,536, filed on Apr. 30, 2019, granted, now 11,090,261, issued on Aug. 17, 2021.
Application 16/398,536 is a continuation of application No. 15/783,160, filed on Oct. 13, 2017, granted, now 10,278,918, issued on May 7, 2019.
Application 15/783,160 is a continuation of application No. 14/169,339, filed on Jan. 31, 2014, granted, now 9,795,560, issued on Oct. 24, 2017.
Claims priority of provisional application 61/759,530, filed on Feb. 1, 2013.
Prior Publication US 2024/0285519 A1, Aug. 29, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 9/00 (2006.01); A61K 31/417 (2006.01)
CPC A61K 9/0048 (2013.01) [A61K 31/417 (2013.01)] 23 Claims
OG exemplary drawing
 
1. An aqueous ophthalmic solution, consisting of:
a. about 0.1% (w/v) to about 4% (w/v) of phentolamine or a pharmaceutically acceptable salt thereof;
b. about 1% (w/v) to about 6% (w/v) of at least one polyol compound selected from the group consisting of mannitol, glycerol, propylene glycol, ethylene glycol, sorbitol, and xylitol;
c. about 0.1 mM to about 10 mM of at least one buffer;
d. water; and
e. optionally one or more of a poly (C2-4alkylene) glycol polymer, dextran, cellulose agent, carbohydrate, alkali metal halide, alkaline earth metal halide, boric acid, cyclodextrin, dextrose, glycerin, urea, preservative, viscosity modifying agent, solubilizing agent, surfactant, demulcent polymer, wetting agent, or water-miscible solvent;
wherein the solution has a pH in the range of 4.0 to 7.5.